Business OpportunityUpdated on 20 March 2026
Tel-eVax
CEO at Evvivax srl
Roma, Italy
About
Tel-eVax is a genetic vaccine that targets the telomerase enzyme (TERT), overexpressed in tumor cells, to stimulate an antitumor immune response. It has been shown to be safe, immunogenic, and to increase survival in over 100 dogs with B-cell lymphoma in Italy and the USA when combined with standard chemotherapy, with potential application in other tumors and human models.
Organisation
Similar opportunities
Business Opportunity
- TRL 6
- Other
- ATMPs
- Oncology
- Proteomics
- Bioinformatics
- Consortium partners
- Research collaboration
- Neoplasms/cancer/oncology
Linda Nocchi
Scientific Project Manager at Nouscom
Rome, Italy